- Phosphate-based excipients provide higher bulk densities and enable the reduction of the tablet sizes.
- Multiple patients’ needs such as vegan and lactose-free formulations can be met by using phosphate-based excipients.
Brenntag, the global market leader in chemicals and ingredients distribution, today announced that it is offering Budenheim phosphate-based excipients to its Pharma customers in Germany, France, Benelux, Poland and the Nordics. The portfolio of Budenheim comprises materials with a unique high bulk density, helping customers to minimize the tablet size. This can be used and applied in the development of mini tablets.
Budenheim’s highly functional phosphate-based excipients are produced in Germany. They provide various solutions for the development of pharmaceutical dosage forms. In the case of mini tablets, they facilitate the production of small size tablets with excellent mechanical strength, also by using in a direct compression process. In addition, phosphate-based excipients offer the possibility of producing vegan and lactose-free medicines.
Mini tablets are a modern dosage form, having gained popularity and market share in the past years. They offer a solution if the ingestion of tablets is a problem, such as in pediatric dosages. Young patients often have difficulties taking tablets, but the size of the solid dosage form can also cause problems for adult patients suffering from problems swallowing.
With tablet diameters of 1-3 millimeter (mm) and a thickness below 2 mm, mini tablets are ideal candidates to overcome these issues. They can be either formulated into tablets, film-coated tablets, hard capsules, sachets or other oral solid dosage forms. With Budenheim’s solutions, tablet heights can be reduced by up to 50%, compared to the usage of lactose-based excipients.
Elvira Edel, Industry Market Manager Excipients Brenntag Specialties Pharma EMEA, states: “Mini tablets based on Budenheim phosphate are a huge value add in many use cases. We are happy that the cooperation with Budenheim allows us to offer this highest quality pharmaceutical ingredient to our tablet producing customers from Germany, France, Benelux, Nordics and Poland.”
About Budenheim:
Budenheim is a globally operating specialty chemical company. With its innovative portfolio, the chemical specialist provides sustainable products, services, and application concepts for various markets. In close cooperation with its customers, Budenheim is dedicated to advancing nutrition, health, safety, and the preservation of resources. With sites in Germany, Spain, the Netherlands, the USA, Mexico, China, Singapore, and India, Budenheim generates annual revenue of several hundred million euros and employs more than 1,350 people. For more information about Budenheim, visit:www.budenheim.com
